Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Jurnal Ners Journal of Pharmaceutical and Sciences.
Putri, Meisya Diffa Amalia
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Konjugat Antibodi-Obat sebagai Pendekatan Pengobatan Alternatif untuk Kanker Paru Bukan Sel Kecil (NSCLC) di Tengah Peningkatan Resistensi Terapi: Tinjauan Sistematis Putri, Meisya Diffa Amalia; Kasasiah, Ahsanal
Jurnal Ners Vol. 9 No. 2 (2025): APRIL 2025
Publisher : Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/jn.v9i2.38473

Abstract

Kanker paru bukan sel kecil atau non-small cell lung cancer (NSCLC) adalah jenis kanker paru yang paling umum dan memiliki tantangan signifikan dalam pengobatan, terutama terkait dengan resistensi terhadap terapi yang ditargetkan. Resistensi ini sering disebabkan oleh mutasi sekunder atau aktivasi jalur pensinyalan alternatif, yang mengurangi efektivitas terapi yang ada. Konjugat antibodi-obat atau antibody-drug conjugate (ADC) telah muncul sebagai pendekatan terapeutik inovatif yang menjanjikan untuk mengatasi tantangan tersebut. Konjugat antibodi-obat atau antibody-drug conjugate (ADC) menggabungkan antibodi monoklonal spesifik dengan muatan aktif, memungkinkan pengiriman terapi yang lebih tepat dan mengurangi dampak pada jaringan sehat. Dalam artikel ini, kami mengeksplorasi berbagai ADC yang sedang dalam pengembangan dan telah menunjukkan efikasi sebagai alternatif terapi untuk NSCLC, termasuk BL-B01D1, trastuzumab deruxtecan, dan sacituzumab govitecan. Meskipun ADC menawarkan harapan baru, perhatian perlu diberikan pada efek samping signifikan, seperti neutropenia dan anemia, yang dapat mempengaruhi kualitas hidup pasien. Penelitian lebih lanjut diperlukan untuk mengeksplorasi efektivitas jangka panjang, biomarker yang terkait, dan strategi manajemen efek samping. Dengan pendekatan ini, ADC berpotensi menjadi bagian penting dalam strategi terapeutik untuk NSCLC.
Evaluasi Bukti dari Uji Klinis tentang Interaksi Antibiotik dan Antasida: Suatu Tinjauan Sistematis Literatur Al Qindy, Wildan Hidayah; Nurdin, Fitri Oktaviani; Khaerunisa, Aulia; Putri, Meisya Diffa Amalia; Hilmi, Indah Laily; Putri, Mukarromah Dita
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 4 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i4.1093

Abstract

Drug interactions between antibiotics and antacids represent an important clinical issue that can affect therapeutic efficacy and increase the risk of treatment failure. The concurrent use of these drug classes frequently occurs in clinical practice, particularly in patients receiving antibiotic therapy who also present with gastrointestinal complaints. This systematic literature review aims to evaluate the clinical trial evidence regarding antibiotic–antacid interactions, focusing on pharmacokinetic and pharmacodynamic mechanisms, clinical implications, and current research limitations. Relevant articles were identified through PubMed, Google Scholar, and other scientific databases using standardized keywords. Literature selection followed the PRISMA guidelines to ensure the quality and relevance of included studies. The analysis revealed that antacids and proton pump inhibitors (PPIs) can significantly reduce the bioavailability of antibiotics, especially fluoroquinolones and tetracyclines, through chelation with metal ions and by increasing gastric pH, thereby impairing drug absorption. Concomitant use of antibiotics and PPIs was also associated with a higher risk of Clostridioides difficile infection (CDI), particularly in elderly or comorbid patients. Conversely, newer acid-suppressing agents such as vonoprazan demonstrated good efficacy in Helicobacter pylori eradication regimens without compromising antibiotic activity. Despite these findings, most studies were retrospective, with limited sample sizes and specific populations. Therefore, large-scale prospective clinical trials are needed to strengthen the evidence base. A comprehensive understanding of antibiotic–antacid interactions is essential to support rational, safe, and effective prescribing practices in clinical settings.
Co-Authors Ahsanal Kasasiah Al Qindy, Wildan Hidayah Indah Laily Hilmi Khaerunisa, Aulia Nurdin, Fitri Oktaviani Putri, Mukarromah Dita